



Corrigendum: High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele *CFHR3* B*

Richard B. Pouw^{1,2}, Irene Gómez Delgado³, Alberto López Lera⁴, Santiago Rodríguez de Córdoba⁵, Diana Wouters¹, Taco W. Kuijpers^{2,6} and Pilar Sánchez-Corral^{3*}

¹ Department of Immunopathology, Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ² Department of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ³ Complement Research Group, Hospital La Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain, ⁴ Immunology Unit, Hospital La Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain, ⁵ Biological Research Center (CIB)-CSIC, Center for Biomedical Network Research on Rare Diseases (CIBERER), Madrid, Spain, ⁶ Department of Blood Cell Research, Sanquin Research and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

Keywords: complement, factor H, factor H-related protein 3, *CFHR3* gene, atypical hemolytic-uremic syndrome

OPEN ACCESS

Approved by:
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

***Correspondence:**
Pilar Sánchez-Corral
pilar.sanchez-corral@idipaz.es

Specialty section:
This article was submitted to
Molecular Innate Immunity,
a section of the journal
Frontiers in Immunology

Received: 12 December 2019

Accepted: 16 December 2019

Published: 24 January 2020

Citation:
Pouw RB, Gómez Delgado I, López Lera A, Rodríguez de Córdoba S, Wouters D, Kuijpers TW and Sánchez-Corral P (2020) Corrigendum: High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele *CFHR3* B*. *Front. Immunol.* 10:3073. doi: 10.3389/fimmu.2019.03073

A Corrigendum on

High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele *CFHR3* B*

by Pouw, R. B., Gómez Delgado, I., López Lera, A., Rodríguez de Córdoba, S., Wouters, D., Kuijpers, T. W., et al. (2018). *Front. Immunol.* 9:848. doi: 10.3389/fimmu.2018.00848

There is an error in the **Acknowledgments** statement. The correct name for the funder “Spanish Ministerio de Economía y Competitividad” is “Spanish Instituto de Salud Carlos III.”

A correction has been made to the **Acknowledgments** section:

“We appreciate the technical assistance of Lorena Risueño, César Vélez, and Álex Otero in the management of biological samples of patients and controls. We thank Rosario Madero (IdiPAZ Biostatistics) for statistical help, and Vega Mauleón and Hoi Tong (IdiPAZ UCICEC) for blood sampling of the healthy Spanish volunteers. This study was funded by the Spanish Instituto de Salud Carlos III and the European Program FEDER (grants PI12/00597 and PI16/00723 to PS-C, and grant SAF2015-66287-R to SR), and by the Complement II-CM network (B2017/BMD-3673). RP and TK received funding from the European Union's seventh Framework program under EC-GA no. 279185 (EUCLIDS; www.euclids-project.eu). AL is supported by the Spanish Center for Biomedical Network Research on Rare Diseases (CIBERER).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2020 Pouw, Gómez Delgado, López Lera, Rodríguez de Córdoba, Wouters, Kuijpers and Sánchez-Corral. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.